Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.40 Average Target Price from Brokerages

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been given an average recommendation of “Moderate Buy” by the fifteen analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $17.40.

Several brokerages recently commented on ATEC. Stifel Nicolaus cut their price objective on Alphatec from $16.00 to $13.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. TD Cowen raised their target price on Alphatec from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Wall Street Zen downgraded Alphatec from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Stephens initiated coverage on Alphatec in a research note on Thursday, July 23rd. They set an “overweight” rating and a $15.00 price target for the company. Finally, BMO Capital Markets upped their price target on shares of Alphatec from $11.00 to $12.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th.

Insider Buying and Selling at Alphatec

In other Alphatec news, General Counsel Tyson Marshall sold 8,168 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $9.65, for a total transaction of $78,821.20. Following the completion of the sale, the general counsel owned 630,398 shares of the company’s stock, valued at approximately $6,083,340.70. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Patrick Miles acquired 115,000 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were bought at an average price of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the purchase, the chief executive officer owned 5,893,551 shares in the company, valued at $51,922,184.31. This trade represents a 1.99% increase in their position. The disclosure for this purchase is available in the SEC filing. 13.48% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Next Century Growth Investors LLC grew its holdings in Alphatec by 6.1% during the 4th quarter. Next Century Growth Investors LLC now owns 2,418,298 shares of the medical technology company’s stock valued at $50,881,000 after buying an additional 138,915 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Alphatec by 26.9% in the first quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock worth $27,863,000 after buying an additional 543,059 shares in the last quarter. Emerald Advisers LLC boosted its position in shares of Alphatec by 10.4% during the first quarter. Emerald Advisers LLC now owns 1,807,307 shares of the medical technology company’s stock worth $19,664,000 after acquiring an additional 169,578 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Alphatec by 11.3% during the fourth quarter. BNP Paribas Financial Markets now owns 708,548 shares of the medical technology company’s stock worth $14,908,000 after acquiring an additional 71,933 shares during the last quarter. Finally, Granite Investment Partners LLC grew its stake in Alphatec by 4.7% during the first quarter. Granite Investment Partners LLC now owns 1,195,156 shares of the medical technology company’s stock valued at $13,003,000 after acquiring an additional 54,043 shares in the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Stock Performance

Shares of ATEC stock opened at $10.17 on Tuesday. The company has a quick ratio of 1.07, a current ratio of 1.89 and a debt-to-equity ratio of 40.35. The company has a 50 day moving average price of $9.42 and a 200-day moving average price of $9.65. Alphatec has a 52 week low of $6.82 and a 52 week high of $23.29. The firm has a market capitalization of $1.57 billion, a PE ratio of -14.32 and a beta of 0.85.

Alphatec (NASDAQ:ATEC) last issued its earnings results on Tuesday, August 4th. The medical technology company reported $0.07 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.07. The company had revenue of $213.51 million for the quarter, compared to analysts’ expectations of $211.26 million. Alphatec had a negative net margin of 13.49% and a negative return on equity of 6,752.24%. The firm’s quarterly revenue was up 15.1% on a year-over-year basis. During the same quarter last year, the company posted $0.02 earnings per share. As a group, equities research analysts expect that Alphatec will post -0.45 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on improving the surgical treatment of spinal disorders. The company develops and commercializes products designed to support spine surgery, including implants, biologics, surgical instruments and related technologies.

Its portfolio is intended for procedures addressing conditions such as spinal deformities, degenerative disc disease and other disorders affecting the spine. Alphatec emphasizes surgeon-focused solutions and integrated technologies that support preoperative planning, intraoperative decision-making and the placement of spinal implants.

Headquartered in Carlsbad, California, Alphatec serves hospitals, surgeons and other healthcare providers in the United States and select international markets.